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Abstract
Background: Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive inborn error of cholesterol metabolism
syndrome with neurocognitive manifestations. SLOS is the result of mutations in the gene encoding the
7-dehydrocholesterol reductase, which results in the elevation of the cholesterol precursor 7-dehydrocholesterol
(7-DHC). Previous reports indicate that intellectual disability, behavioral disturbances, and autism symptoms are
frequently part of the SLOS behavioral phenotype. In the current study, we characterize the developmental
history and current behavior of 33 individuals with SLOS aged 4 to 23 years and report on biomarkers 7-DHC
and 8-DHC in relation to cognition and behavior.
Methods: This was an observational case series, wherein participants with SLOS underwent extensive behavioral
evaluation of cognitive function, adaptive function, autism symptoms, and problem behaviors, in addition to
parent report of developmental milestones. Serum and CSF were contemporaneously obtained from the majority of
participants.
Results: Developmental milestones such as walking, talking, and toileting were uniformly delayed. Overall levels of
cognitive and adaptive functioning were low; no participant received adaptive behavior scores in the average range,
and the mean level of cognitive functioning in the full sample was in the moderate range of impairment. Aggressive
behavior was present in nearly half of participants. Although the majority of participants had elevated scores on the
gold standard autism diagnostic instruments, only about half of participants received a clinical diagnosis of autism
spectrum disorder. Finally, while CSF cholesterol was not found to correlate with cognitive or adaptive functioning,
both serum and CSF 7-DHC and 8-DHC (and their ratios with cholesterol) were moderately and negatively correlated
with functioning in this group.
Conclusions: A history of developmental delay, followed by intellectual disability, is common in individuals with SLOS.
Although autism spectrum disorder appears to be a frequent diagnosis in this population, it is apparent that the low
level of functioning observed in SLOS may artificially inflate scores on standard autism assessments. Our findings
further support that cholesterol precursors 7-DHC and 8-DHC are important biomarkers of the level of functioning in
SLOS, especially regarding cognitive abilities, and thus may be to explore as mediators within the context of treatment
trials.
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Background
Smith-Lemli-Opitz syndrome (SLOS; OMIM #270400)
is a biochemically defined syndrome with neurocognitive
and developmental manifestations. In SLOS, endogenous
cholesterol synthesis has been impaired at the penultimate
step of the conversion of 7-dehydrocholesterol (7-DHC) to
cholesterol, resulting in lowered serum cholesterol levels
and elevated cholesterol precursor 7-DHC [1, 2]. SLOS is
autosomal recessive and is caused by a mutation of the
DHCR7 gene (located on chromosome 11q12-13) [3]. The
estimated incidence of SLOS is 1 in 39,000 births [4].
SLOS is diagnosable during the fetal period, with diverse
presentations of specific dysmorphic features reported in
the literature [1, 5]. Among them are cutaneous syndac-
tyly of the second and third toes, post-axial polydactyly of
the hands or feet, cleft palate, abnormal gingivae, and
hypospadias. Other dysmorphic features may include
microcephaly, ptosis, epicanthal folds, short nasal bridge,
bitemporal narrowing, and micrognathia. Less commonly
reported features include hammertoes, dorsiflexed hallu-
ces, cutaneous syndactyly on the fingers, and clinodactyly,
as well as medical problems affecting multiple systems [5].
Cognitive and language development in SLOS
Developmental delay and behavioral problems were re-
ported early on in the description of SLOS [6]. Tierney
et al. [7] conducted the largest behavioral phenotyping
study of the condition, which included 56 subjects that
ranged in age from infancy to age 32. Only about half of
those subjects had mental ages above 18 months. With
respect to language, as measured by the MacArthur
Child Development Inventory [8], the majority of partic-
ipants (78 %) were found to have expressive language
skills equivalent to a child under 30 months, with 43 %
under 8 months. Another group conducted cognitive
and behavioral testing on a sample of 14 subjects with
SLOS aged 3–16, finding cognitive scores that ranged
from 28 to 75 [9].
Behavior problems and autism spectrum disorder
Previous reports indicated that individuals with SLOS
engage in multiple types of maladaptive behaviors,
including frequent self-injury and other stereotypic
movements. In the Tierney et al. phenotyping study, half
of the 17 participants with Autism Diagnostic Interview-
Revised (ADI-R; [10]) administrations exceeded the
cutoff for autism derived from this measure. Of note, the
percentage above the cutoff was lower (22 %) for those
who had already started cholesterol supplementation by
age 5 (age at which diagnostic criteria are assessed per
history reported on the ADI-R), compared to those who
started after age 5 (88 %) [7].
In a subsequent study by Sikora et al., 71 % of 14 indi-
viduals with SLOS met the criteria for a diagnosis of
autistic disorder or pervasive developmental disorder,
not otherwise specified based on completion of a semi-
structured interview informing the Diagnostic and
Statistical Manual for Mental Disorder, 4th edition
(DSM-IV) checklist [9]. This study also employed the
Autism Diagnostic Observation Schedule (ADOS) [11]
and the Gilliam Autism Rating Scale [12]; it is worth
noting that the rate of classification of autism spectrum
disorder (ASD) varied by scale. Eighty-six percent were
above the cutoff on the ADOS, while only 21 %
exceeded the cutoff on the Gilliam.
The specificity of the gold standard measures of ASD
symptoms (ADI-R and ADOS) is low in individuals with
severe and profound intellectual disability (ID) [13, 14],
and these measures must therefore be used with caution
in individuals with a nonverbal mental age (NVMA) of
less than 18 months and/or co-occurring physical or
sensory disabilities. This appears especially true in SLOS,
as a substantial proportion of individuals have severe or
profound ID and associated neurological features that
affect physical and sensory functioning.
Biomarkers of SLOS and behavior
Studies have begun exploring phenotypes in relation to
biochemical manifestations of the disorder. Specifically,
the relationships among markers of abnormal sterol me-
tabolism and aspects of the behavioral phenotype in SLOS
have now been examined in several reports [9, 15, 16].
Sikora et al. examined correlations of autism symptom
measures with cholesterol, 7-DHC, and 8-DHC and found
no significant correlations [9]. Another recent study tested
whether the ratio of 7-DHC+ 8-DHC to cholesterol was
related to IQ and/or challenging behavior in a small
sample (n = 13) of children diagnosed with SLOS. This
study did not find a relationship of sterol levels with
IQ but did find a relationship between some specific
maladaptive behaviors (described as biobehavioral) and
the ratio of combined 7-DHC and 8-DHC to choles-
terol [15].
Sparks et al. [16] measured the levels of serotonin and
dopamine metabolites, 5-hydroxyindoleacetic acid
(5HIAA), and homovanillic acid (HVA) in the cerebral
spinal fluid (CSF) of 21 individuals with SLOS in an at-
tempt to correlate anatomical severity scores, Aberrant
Behavior Checklist scores, and concurrent sterol biochem-
istry. No evidence was found for correlation among CSF
5HIAA, HVA, 7-DHC, and 8-DHC, nor were correlations
found with the behavioral measures.
The goal of the current study was to provide an updated
description of cognitive and behavioral characteristics of
children and adolescents with SLOS. Emphasizing early
development, cognitive and adaptive functioning, and
recently updated diagnostic changes and algorithms for
diagnostic measures of autism [17], we were interested in
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exploring associated symptoms while accounting for the
global developmental delays and medical problems found
in this population. We also sought to determine whether
serum or CSF cholesterol, 7-DHC, or 8-DHC serve as use-
ful biological markers of cognitive impairment in SLOS.
Methods
Participants
This study describes a subset of 33 research participants
with SLOS who underwent the full complement of behav-
ioral assessments, taken from a longitudinal natural
history study of SLOS (NCT00001721) or from the
baseline visit of a clinical trial of simvastatin in individuals
with SLOS (NCT00064792) (Table 1). The diagnosis of
SLOS was confirmed biochemically and molecularly for all
patients. Two of these patients were previously described
in Tierney et al. [7]. The behavioral assessment battery
was completed in 1–2 days; when more than one behav-
ioral assessment was available from the natural history
study, the earliest visit was used. Children from families
primarily using languages other than English were
excluded from this analysis because measures were admin-
istered in English.
Ethics, consent, and permissions
Families from across North America participated in stud-
ies that occurred either at the National Institutes of Health
(NIH) (Bethesda, MD) or at the Kennedy Krieger Institute
(Baltimore, MD), based on the protocols approved by the
institutional review boards of the Johns Hopkins Medical
Institutions and the Eunice Kennedy Shriver National
Institute for Child Health and Human Development.
Informed consent and assent, if applicable, was obtained
for all subjects.
Neurocognitive and behavioral assessment
A standard battery was administered to each participant,
including assessments of cognitive ability, adaptive behav-
ior, problem behaviors, and symptoms of autism spectrum
disorder. Given the range of ability in this cohort, no single
cognitive test was appropriate for all participants. The
Stanford-Binet Intelligence Test [18] was attempted; if the
participant was unable to achieve the basal score on at least
four subtests, then the Mullen Scales of Early Learning
[19] was administered. Full-scale IQ (FSIQ), nonverbal IQ
(NVIQ), and verbal IQ (VIQ) are reported for the
Stanford-Binet; for comparability (and to accommodate
Table 1 Summary of patient characteristics
KKI NIH Full sample
n 22 11 33
Male, n (%) 13 (59 %) 6 (55 %) 19 (58 %)
Age, years (M ± SD) 8.04 ± 3.63 10.84 ± 6.29 8.98 ± 4.78
Anatomical severity (M ± SD) 13.45 ± 7.22 11.73 ± 5.12 12.88 ± 6.56
Simvastatin, n (%) 0 1 (9 %) 1 (3 %)
Cholesterol supplementation, n (%) 22 (100 %) 8 (73 %) 30 (91 %)
Clinical judgment of autism diagnosis
ASD 15 (68 %) 3 (27 %) 18 (55 %)
Nonspectrum 7 (32 %) 8 (73 %) 15 (45 %)
ADOS classification
Autism 16 (73 %) 4 (36 %) 20 (61 %)
Autism spectrum 2 (9 %) 2 (18 %) 4 (12 %)
Nonspectrum 4 (18 %) 5 (45 %) 9 (27 %)
ADI-R classification
Autism 11 (50 %) 8 (73 %) 19 (58 %)
Nonspectrum 11 (50 %) 3 (27 %) 14 (42 %)
Vineland-II Adaptive Behavior Composite (M ± SD) 49.18 ± 17.56 58.82 ± 12.94 52.39 ± 16.60
Nonverbal IQ (M ± SD) 47.45 ± 24.22 45.15 ± 17.56 46.68 ± 21.96
Verbal IQ (M ± SD) 39.44 ± 30.23 41.50 ± 17.86 40.17 ± 26.19
Full-scale IQ (M ± SD) 44.20 ± 25.26 42.41 ± 16.75 43.57 ± 22.33
Note: IQ was estimated with the Mullen Scales of Early Learning (KKI, n = 8; NIH, n = 6) or the Stanford-Binet Scales of Intelligence (KKI, n = 15; NIH, n = 5). Two
individuals (KKI) were each missing VIQ and FSIQ. ASD refers to any of the DSM-IV pervasive developmental disorders
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out-of-age-range testing), the corresponding scores were
calculated from the Mullen using developmental quotients
(DQ; mental age divided by chronological age). For the
Mullen, NVDQ was calculated from the nonverbal mental
age, the average of the Visual Reception and Fine Motor
subscales, divided by chronological age, while VDQ was
calculated from the verbal mental age, the average of
the Expressive and Receptive Language subscales, di-
vided by chronological age. Full scale was the average
of NVDQ and VDQ. Hereafter, we use the term IQ to
refer to both IQ and DQ scores. IQ scores have a mean
of 100 and a standard deviation of 15; by convention, IQ
scores are described using the following categories: ≥85
average, ≥70 borderline, ≥55 mild impairment, ≥40
moderate impairment, ≥25 severe impairment, and <25
profound impairment.
Adaptive behavior was assessed with the parent report
form of the Vineland Adaptive Behavior Scales, 2nd edition
[20]. The Vineland-II yields standard scores (mean = 100,
standard deviation = 15) on four domains: Communication,
Daily Living Skills, Socialization, and Motor Skills (for
subjects younger than 8 years), as well as the Adaptive
Behavior Composite. Scores less than 70 are consid-
ered impaired (70–79 borderline; 80–89 below average;
90+ average).
Finally, the gold standard autism diagnostic battery
was administered: the play-based Autism Diagnostic
Observation Schedule (ADOS; [11]), the semi-structured
parent interview Autism Diagnostic Interview-Revised
(ADI-R; [10]), and the clinical judgment of the DSM-IV-
TR criteria. Both the ADOS and ADI-R are diagnostic
instruments that produce total and symptom domain
scores, which are evaluated against a cutoff for suspicion
of autism (higher threshold) or autism spectrum (lower
threshold, ADOS only). Using algorithms modified in
2007, the ADOS also produces calibrated severity scores
(CSS), which standardize scores according to age and
language ability and range from 1 to 10 [17]. The ADI-R
is an extensive interview that covers past and current
behaviors, as well as information about developmental
milestones and problem behaviors. Standard procedures
were followed for achieving and maintaining research re-
liability on the ADI-R and the ADOS. Both the ADI-R
and the ADOS were administered for research purposes
here, regardless of the participants’ mental age. It should
be noted that the ADI-R suggested nonverbal mental
age requirement is 24 months and caution should be
used for interpreting both the ADI-R and ADOS in
individuals with low nonverbal mental age.
Clinical judgment was completed by doctoral-level cli-
nicians with extensive experience in assessing individuals
with intellectual disability and the diagnosis of autism
spectrum disorder, using all available information and
basing their judgment on a checklist of the Diagnostic
and Statistical Manual for Mental Disorder, 4th edition
(DSM-IV; [21]) criteria for autistic disorder and perva-
sive developmental disorder, not otherwise specified
(PDD-NOS). Hereafter, we refer to either autistic
disorder or PDD-NOS with the omnibus term, autism
spectrum disorder (ASD), consistent with the autism
spectrum disorder term included in the 2013 publication
of the Diagnostic and Statistical Manual for Mental
Disorder, 5th edition (DSM-5; [22]) (although partici-
pants in the current study were not evaluated with the
DSM-5 criteria).
Other evaluations
Concurrent blood samples were collected from the
majority (n = 30) of participants. CSF was obtained
contemporaneously on a subset (n = 26) of those partici-
pants. With one exception of a 12-day lag, all samples
and data were collected during a 5-day admission to the
NIH Clinical Center and/or the Kennedy Krieger
Institute, during which time the behavioral assessments
were also conducted. Both serum and CSF were analyzed
for levels of cholesterol, 7-DHC, and 8-DHC. Severity of
anatomical abnormality was rated using the severity
scale developed by Bialer and later refined by Kelley et
al. [23], based on categories of brain, oral, acral, eye,
heart, kidney, liver, lung, bowel, and genitalia abnormal-
ities. Possible scores range from 0 to 100, as ratings that
range from 0 to 2 for each item are normalized.
Results
Participant characteristics are summarized in Table 1.
Individual results of the behavioral evaluation are shown
in Table 2. The 33 participants ranged in age from 4 to
23 years (M ± SD = 8.98 ± 4.78), and severity scores
ranged from 6 to 33. All but three participants were
reported to currently take cholesterol supplementation.
Attainment of developmental milestones
Information on developmental milestones was obtained
from the ADI-R. Generally, milestones were delayed.
Notable, however, was the wide age range during which
attainment of milestones occurred; children were generally
taking first steps and using first words in mid-to-late
childhood. Walking was delayed in most participants; only
four (12 %) individuals walked prior to 18 months, an
additional 19 (58 %) participants walked by 36 months,
seven (21 %) participants walked between 36 and
96 months, and three (9 %) subjects (aged 5–7 years) were
not yet walking at the time of evaluation. Toilet training
data was missing for five participants; among the
remaining 28 with data, nighttime bladder control was
achieved between 42 and 138 months (n = 11, 39 %) or not
at all (n = 17, 61 %). Ten (36 %) participants had achieved
daytime bladder control, at ages ranging from 42 to
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144 months. Those same ten subjects had also achieved
bowel control (age of attainment range from 42 to
138 months).
Language milestones were also delayed; only ten par-
ticipants (30 %) used their first words by 24 months.
The remainder were either not speaking at the time of
evaluation (n = 4, 12 %) or first used language between
27 and 121 months (n = 19, 58 %). One third (n = 11) of
participants were not using phrase speech at the time of
evaluation; among the remaining, only five (15 %) used
phrase speech prior to 33 months. The age of first use of
phrases ranged up to 126 months. A loss of language
Table 2 Cognitive, adaptive behavior, and ASD status




K01 M – 7.13 11 n/a 32 42 43 40 SB AUT AUT ASD
K04 M – 8.67 22 48 29 10.1 12.0 11.1 MSEL AUT AUT ASD
K05 F N 17.53 17 60 19 9.5 8.1 8.8 MSEL AUT AUT ASD
N09 M N 23.27 11 24 61 66 68 66 SB AUT AUT ASD
K12 M N 9.08 6 18 71 56 77 65 SB NS NS NS
K13 M N 10.61 17 24 53 60 3.2 56 SB AUT NS ASD
K18 F N 12.02 22 48 34 42 43 40 SB AUT NS ASD
K24 F Y 7.58 11 24 50 46 – – SB AUT AUT ASD
K25 F – 10.08 11 12 60 60 49 52 SB NS NS NS
K26 M – 13.32 6 42 45 51 49 48 SB AUT AUT ASD
K33 M Y 5.58 33 n/a 43 33.6 17.9 25.8 MSEL AUT AUT ASD
K34 M – 5.68 11 22 32 17.6 8.8 13.2 MSEL AUT NS ASD
N36 F N 11.06 6 18 50 18.6 20.5 19.5 MSEL AUT AUT NS
N45 M Y 10.63 6 17 75 62 59 59 SB NS NS NS
K55 F – 4.41 11 15 69 53 56 52 SB AUT AUT ASD
K56 F N 6.09 6 30 78 74 93 83 SB NS NS NS
N58 F Y 8.05 22 n/a 72 60 56 56 SB NS NS NS
K60 M N 4.74 11 20 67 70 – – SB AS AUT ASD
K61 M Y 6.30 17 20 63 66 59 61 SB NS NS NS
K62 F Y 10.30 11 28 54 59 1.8 51 SB AUT NS NS
K63 F – 5.41 22 54 36 20.8 18.5 19.7 MSEL AUT AUT ASD
K64 M N 4.03 6 17 66 69 83 75 SB AUT NS NS
K66 M Y 4.08 11 18 72 103 86 94 SB AUT NS NS
K68 F Y 4.08 11 55 53 64 57 58 SB AS AUT ASD
K70 M – 13.25 11 21 25 15.1 12.6 13.9 MSEL AUT NS ASD
N71 M – 4.97 17 36 62 53.4 55.1 54.2 MSEL NS AUT NS
N72 M – 9.73 11 18 60 43 43 40 SB AS AUT ASD
K73 M N 6.96 6 30 31 22.3 10.8 16.6 MSEL AUT AUT ASD
N78 F – 20.99 17 36 36 42 43 40 SB AS AUT NS
N79 F – 13.63 22 96 37 11.7 8.3 10.0 MSEL AUT AUT NS
N86 F N 3.95 6 24 70 58.5 29.8 44.1 MSEL NS NS NS
N87 M N 7.49 6 24 61 37.6 31.5 34.6 MSEL NS AUT ASD
N97 M – 5.49 11 23 63 43.8 42.3 43.1 MSEL AUT AUT NS
Note. ID indicates site; those beginning with K were seen at the KKI, and those beginning with N were seen at the NIH. IQ with one decimal place indicates
developmental quotient (mental age divided by chronological age) used, while scores with no decimal places indicate IQ used. Double dash (–) indicates missing
data. Only one subject (N09) was on simvastatin at the time of evaluation. All subjects except N78, N79, and N87 were taking cholesterol supplementation at
evaluation. n/a for age of walking indicates that the child was not yet walking at evaluation; ages are in months
Hearing imp hearing impairment, VABS-II ABC Vineland-II Adaptive Behavior Composite, NVIQ nonverbal IQ, VIQ verbal IQ, FSIQ full-scale IQ, ADOS Autism Diagnos-
tic Observation Schedule, ADI-R Autism Diagnostic Interview, Revised, SB Stanford-Binet Intelligence Scales, MSEL Mullen Scales of Early Learning, NS nonspectrum,
AS autism spectrum, AUT autism, ASD autism spectrum disorder
Thurm et al. Journal of Neurodevelopmental Disorders  (2016) 8:12 Page 5 of 10
skills was reported for only three (9 %) participants; these
losses were reported to occur in late toddlerhood (33 and
35 months) or mid-to-late childhood (63 months). Those
who lost language in toddlerhood were reported to have
not yet regained those skills (at age 7 and 20 years,
respectively), while the loss in later childhood lasted for
less than 1 year. No loss was reported to coincide with an
illness.
Cognitive and adaptive functioning
Participants received either the Stanford-Binet (n = 20,
61 %) or the Mullen Scales of Early Learning (n = 13,
39 %) as a test of cognitive functioning. Eight (62 %) of
the 13 participants who received the Mullen were out of
age range for the test (which is standardized up to
5 years, 8 months). Two participants received only the
nonverbal scales, so for the purposes of summarizing
cognitive function in this paragraph, their full-scale scores
were imputed at those values. The majority (n = 30, 91 %)
of participants had a nonverbal mental age greater than
18 months, and n = 26 (78 %) had a nonverbal mental age
greater than 24 months. The mean level of functioning in
the full sample was in the moderate range of impairment
(mean FSIQ, 44.44 ± 22.11), but the full range of im-
pairment categories was represented: profound (n = 8,
24 %), severe (n = 2, 6 %), moderate (n = 12, 36 %),
mild (n = 7, 21 %), borderline (n = 3, 9 %), and aver-
age (n = 1, 3 %). Among the 31 participants with both
NVIQ and VIQ, the average split (NVIQ-VIQ) was
5.78 ± 16.70 and ranged from −21 to +57. Typically, a
split of 10 points is considered clinically significant, and
this was observed in ten (30 %) participants (n = 3, VIQ >
NVIQ; n = 7, NVIQ > VIQ).
Vineland-II scores were consistent with the cogni-
tive testing, in that mean scores in all domains were
in the impaired range of functioning. No participant
had an Adaptive Behavior Composite score in the
average range (M ± SD = 52.39 ± 16.60, range 19–78).
Mean subscale scores were lowest for Daily Living
Skills (M ± SD = 50.21 ± 19.75), followed by Commu-
nication (M ± SD = 55.64 ± 19.90) and Socialization
(M ± SD = 62.94 ± 16.69). The mean Motor Skills
score, assessed only in participants 7 years of age or youn-




Most participants received an ADOS Module 1 (n = 18,
55 %), based on single-word-level speech; eight (24 %)
received a Module 2, based on observed phrase speech;
six (18 %) received a Module 3, and one (3 %) received a
Module 4, both used when the individual is capable of
fluent speech. Most ADOS total scores exceeded the
threshold for autism (n = 20, 61 %); four (12 %) partici-
pants had scores in the autism spectrum range, and nine
(27 %) were in the nonspectrum range (below both
cutoffs). CSS were available for n = 31 participants; the
mean CSS was 5.39 ± 2.20, which is considered to be in
the autism spectrum range.
Scores on the ADI-R exceeded the autism cutoffs for 19
(58 %) participants. On average, participants who
exceeded the autism threshold on either the ADI-R or the
ADOS had greater cognitive impairment than those who
did not. Although the CSS did not significantly correlate
with age or NVIQ, the average NVIQ in the participants
with above autism spectrum-threshold ADOS scores was
42.21 ± 23.68, compared to 58.61 ± 9.89 (F = 3.99, p = .055)
in participants with below-threshold scores. Stratification
by ADI-R classification yielded similar results: 38.86 ±
18.97 in participants who exceeded the autism threshold
versus 57.30 ± 21.88 (F = 6.69, p = .01) in those below.
Based on clinical judgment of all 33 participants, 55 %
(n = 18) were assigned an ASD diagnosis. A nonsignifi-
cant site difference did emerge in clinical judgment;
participants evaluated at the NIH were less likely to be
diagnosed with ASD (NIH = 27 %, KKI = 68 %; Fisher’s
exact test, p = .06). Rates of exceeding the threshold on
the ADOS (NIH = 55 %, KKI = 82 %; Fisher’s exact test,
p = .12) and ADI-R (NIH = 73 %, KKI = 50 %; Fisher’s
exact test, p = .28) were more similar between sites. Six
of the seven participants with nonverbal mental age less
than 24 months had a final clinical judgment of ASD
(and were all seen at Kennedy Krieger Institute (KKI)).
The mean NVIQ in the participants with clinical
judgment of ASD (39.09 ± 19.64) was significantly lower
than in those with clinical judgment of nonspectrum
(55.80 ± 21.71) (F = 5.39, p = .03).
Problem behaviors
Item-level ADI-R data were available for 28 (85 %)
participants; the percentages in this section use these 28
individuals as the denominator. There was no systematic
reason for the missing data; three participants were in
the profound range of functioning, and three were in the
borderline-to-average range. According to parent report,
half (n = 14) of participants currently engaged in definite
aggression towards family members/caregivers, and eight
of those participants were also aggressive towards nonfam-
ily members. Seven (25 %) participants were reported to
currently engage in significant self-injury resulting in tissue
damage; five of those participants were also aggressive
towards family or nonfamily members. Current aggression
was not significantly related to the level of cognitive
impairment; the mean FSIQ was slightly lower in partici-
pants reported to engage in either type of aggression
(39.46 ± 19.07 versus 45.47 ± 16.69; F = 0.79, p = .38), and a
slightly larger proportion of those who demonstrated
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aggressive behavior were classified as severe/profound
(36 % versus 21 %; Fisher’s exact test, p = .68). A similar
pattern was observed for self-injurious behavior.
Serum and CSF cholesterol and sterol levels
Descriptive statistics for serum and CSF cholesterol
and DHC levels are presented in Table 3 (individual
serum and CSF cholesterol and DHC levels are found
in Additional file 1: Table S1). The correspondences
between CSF and serum cholesterol levels were non-
significant for cholesterol (r = .22, p = .28) and 8-DHC
(r = .16, p = .42) but moderate and significant for 7-
DHC (r = .50, p = .01). Age did not correlate with
serum or CSF cholesterol or serum 7-DHC or 8-
DHC, though there were moderate and significant
correlations between age and CSF 7-DHC and 8-DNC
(Table 3). Thus, we elected to proceed with caution
and calculated partial correlations between phenotypic
measures and cholesterol/sterol levels, controlling for
age (Table 3). CSF cholesterol was not significantly
correlated with Vineland-II or IQ scores. However,
serum cholesterol was moderately and positively
correlated with Vineland-II and IQ scores, while both
serum and CSF DHC levels were moderately and
negatively correlated with Vineland-II and IQ. The 7-
DHC + 8-DHC to cholesterol ratio in both serum and
CSF was significantly and moderately-to-strongly
related to all Vineland-II and IQ variables, and serum
was significantly correlated with anatomical severity
score. None of the markers were significantly
correlated with the ADOS calibrated severity score. In
summary, both CSF and serum dehydrosterols,
especially the ratio of 7-DHC + 8-DHC to cholesterol,
performed as biomarkers for general cognitive and
adaptive function.
Discussion
Findings from this study are consistent with previous
reports indicating cognitive and adaptive behavior is
significantly impaired in SLOS. Similar to other studies,
almost one third of SLOS participants were in the severe
to profound range of ID, and only one participant had
average scores. Further, exploration of early developmen-
tal skill attainment indicated motoric, daily living skills,
and language milestones were almost all universally
delayed. However, the age range of attainment was wide
and extraordinarily late in several cases (e.g., walking
attainment up to age 8, language onset up to age 10).
Thus, the general pattern of development is best charac-
terized as one of delay (or stagnation) rather than
deviance, given that most participants achieved mile-
stones, albeit in mid-to-late childhood. This finding has
important implications for intervention studies, because
children may be expected to spontaneously develop new
skills, even far outside of what is considered the typical
window.
With respect to autism symptomatology, several find-
ings of this study are of interest. While the rate of ASD
in this study was similar to that in other published work
(53–71 %) [7, 9], this rate should be interpreted with
caution. First, all estimates of ASD rate in SLOS are ne-
cessarily based on small samples, so the 95 % confidence
intervals surrounding the published point estimates are
extremely wide. Second, while a diagnosis of autism was
common in this SLOS sample, receiving an ASD diagno-
sis was significantly related to NVIQ (ASD < non-ASD).
This was borne out in the between-site differences in
the rate of ASD diagnosis, in that KKI patients were
generally lower functioning. Six of the seven individuals
with a mental age below 24 months were evaluated at
the KKI, and all of these children were given a clinical
Table 3 Serum and CSF cholesterol and sterol levels
M ± SD Range Age Comm DLS Soc Motor ABC NVIQ VIQ FSIQ Anatomical severity
r rp
Serum, mg/dL (n = 30)
Cholesterol 108.90 ± 32.39 (47–181) −.19 .45* .51** .44* .26 .53** .45* .23 .35 −.19
7-DHC 5.70 ± 4.93 (0.044–19.00) .23 −.25 −.24 −.47** −.51* −.31 −.50** −.30 −.48* .23
8-DHC 5.48 ± 5.29 (0.14–28.00) .11 −.14 −.07 −.29 −.29 −.16 −.36 −.23 −.35 .11
Ratio 0.11 ± 0.10 (0.0014–0.39) .25 −.43* −.44* −.59** −.62** −.50** −.65** −.41* −.62** .38*
CSF, μg/mL (n = 26)
Cholesterol 1.83 ± 0.58 (0.96–3.66) .02 −.07 −.13 .02 .03 −.06 .14 −.08 .07 −.19
7-DHC 0.034 ± 0.028 (0–0.097) .47* −.56** −.54** −.52** −.68** −.58** −.52** −.32 −.51* .24
8-DHC 0.072 ± 0.043 (0.006–0.17) .39* −.48* −.43* −.32 −.47* −.46* −.40* −.30 −.38 .18
Ratio 0.065 ± 0.046 (0.0028–0.15) .38 −.53** −.52** −.51** −.66** −.57** −.59** −.34 −.56** .32
Note: r = Pearson correlation; rp = partial Pearson correlation, controlling for age. Ratio is the ratio of combined 7-DHC and 8-DHC, divided by cholesterol concentration.
Sample sizes vary slightly due to missing data; missing n = 2 VIQ and n = 2 FSIQ. Vineland-II motor scores are available only through 7 years of age; thus, the sample size
for serum correlations was n = 23 and for CSF correlations n = 22
*p < .05; **p < .01
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diagnosis (using the DSM-IV criteria for autistic disorder
or PDD-NOS) of ASD. Caution is thus warranted with
respect to whether the DSM-5 criteria would be met.
Specifically, while this study used the DSM-IV criteria
for autism, only a few of the DSM-IV criteria for autistic
disorder explicitly included consideration of developmental
level. The DSM-5 specifically includes criterion E, which
states “These disturbances are not better explained by
intellectual disability or global developmental delay.” While
this criterion is new, the need for such consideration has
been noted for some time; Moss and Howlin [24] urged
extra caution when parsing out clinically relevant symp-
toms of autism from intellectual disability in individuals
with genetic conditions. While this clearly pertains to indi-
viduals with mental ages below 24 months, significant
motor impairments and other congenital problems appear
to complicate the picture to extend these concerns to
higher mental ages as well.
The weaknesses of the diagnostic measures for teasing
out these factors is reflected in the sensitivity and speci-
ficity rates for how cutoffs from these measures compare
to clinical judgment of ASD. Similar to other studies
that have included individuals with profound intellectual
disability [13], specificity of these measures was generally
low (53 % for ADOS, and 67 % for ADI-R), although we
did note higher specificity of the measures in the KKI
sample (ADI-R 100 %, ADOS 57 %) compared to the
NIH sample (ADI-R 37.5 %, ADOS 50 %), which may
have indicated differences in the interpretation of these
measures.
These results were recently supported by a large meta-
analysis of several other genetic disorders associated
with ASD (but not SLOS), in the finding that autism
spectrum classification is often related to the degree of
intellectual disability in genetic disorders associated with
ID [25]. Although the sample size and heterogeneity in
the current study prohibit an idiopathic autism compari-
son, the findings that individuals who had higher ADOS
and ADI-R scores had lower IQ is supported by observa-
tions from other specific genetic disorders associated
with ASD, such as fragile X [26, 27]. Within these gen-
etic disorders, clinically significant ASD symptomatology
appears to dissociate less from cognitive impairment
than it does in idiopathic ASD [28]. In SLOS and other
disorders with other systemic medical problems, this
lack of dissociation with IQ may also relate to the dis-
proportionately delayed early milestone attainment and
related sensory impairments and medical problems,
which may mask as deviancy instead of delay, compared
to pure idiopathic autism [29, 30].
With respect to other behavioral problems frequently
reported in SLOS, this study found high rates of aggres-
sion and self-injury, although not as high as was recently
reported using a different measure [15]. In that study, all
13 children with SLOS were reported to engage in
aggression towards others, self-injurious behaviors, and
destruction of property. The average age of that sample
was about 5 years, considerably younger than the
current study. In the largest phenotyping study, Tierney
et al. reported a history of aggression in 63 % and history
of self-injurious behaviors in 89 % of participants with
SLOS [7]. Similarly high rates of aggression (52 %) and
self-injurious behavior (35 %) were reported in a cohort
from the UK [31]. While there is a great deal of variation
in the rate of aggression in many genetic disorders asso-
ciated with intellectual disability [32], within SLOS, the
methodological differences may be a factor in the differ-
ences found between the current and previous studies.
The ADI-R assessment of aggressive and self-injurious
behaviors was characterized more broadly and included
a history of the behavior in Tierney et al. [7] while the
measure used by Freeman et al. [15] was broadened by
including property destruction. Differences from earlier
studies may also be attributable to the history of choles-
terol supplementation; supplementation at a young age
is more common now than it would have been for the
individuals reported on in previous studies.
Serum sterols (cholesterol and dehydrosterol measure-
ments) and CSF dehydrosterols and their ratio to choles-
terol appear to be linearly related to impairment in
cognitive and adaptive functioning. As such, cognitive and
adaptive functioning may be useful as outcome measures
in any therapeutic trial. One other study demonstrated a
relationship between the dehydrosterol to cholesterol ratio
and problem behavior (though not IQ) [15]; in the current
study, we found moderate-to-strong relationships between
the sterols (and especially the ratios) and measures of
cognitive and adaptive function. Correlations of both 7-
DHC and 8-DHC were generally stronger in the CSF com-
pared to serum, consistent with the blood-brain barrier
separation of peripheral and brain cholesterol metabolism.
Correlations with functioning were strongest with 7-DHC,
consistent with previous findings that congenital abnor-
malities and total severity score increase as residual
enzyme activity decreased and the levels of 7-DHC
increased [33–35]. It is also of note that correlations for
both cholesterol precursors were highest with cognitive
and adaptive areas requiring significant motor skills.
The fact that these biomarkers correlated with contem-
poraneous measures of cognitive and adaptive functioning
has implications for using the biomarker approach to the
measurement of change in treatment trials. Specifically,
this study provides evidence that accumulation of the
aberrant sterol 7-DHC in the brain is related to cognitive
and adaptive functioning. Thus, these sterol levels may
truly be biomarkers that can aid in predicting changes in
cognition and behavior in response to treatment. In
addition, based on a previous study, the relationship of
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these biomarkers to outcomes may also be related to their
relationship to severity of structural brain abnormalities
in this population [36].While cognitive and behavioral
improvements are the end goals for treatment trials of
conditions associated with ID and ASD, very few condi-
tions associated with these disorders currently have the
potential to use such a biomarker to test mediation of
response to treatment [37].
Study limitations
In order to maximally capture the natural history and
current function of SLOS, an untreated sample would be
ideal, but is not feasible. Interpretation of our findings re-
quires acknowledgement that the majority of this cohort
received cholesterol supplementation during their study
participation. However, as cholesterol fails to cross the
blood-brain barrier to an appreciable degree [38, 39], it is
unlikely that any significant differences would be noted in
a control untreated group. Two other limitations likely
had a greater impact on this study. First is the lack of an
appropriate severity scale that takes into account the
behavioral and cognitive function of these patients. The
current scale is based on anatomical characteristics that
reflect the congenital abnormalities of these patients, but
the ratings are sometimes at odds with the clinical evalua-
tions of some of these patients. The second limitation is
the restricted range of SLOS severity of the study cohort;
participants from the KKI were drawn from a trial with
inclusion criteria that prevented any severely affected
patients from enrolling. Patients were between the ages of
4 years and less than 18 years, weighed 10 kg or more,
had residual fibroblast enzymatic activity that was 10 % or
more of the control value (cholesterol synthesis as a
fraction of total sterol synthesis), and had a dehydrochol-
esterol to cholesterol ratio of 1.0 or less.
Conclusions
The current study adds to previous literature by demon-
strating the utility of 7-DHC and 8-DHC, and their ratio
with cholesterol, as biomarkers specific to cognitive and
adaptive function in SLOS. Further, we confirm previous
findings that the vast majority of individuals with SLOS
have ID, although there is a broad range of functioning.
Future directions for research in this area include using
longitudinal data to test whether sterol levels correlate
with functioning over time within subjects, therefore
determining whether these biomarkers may be useful
indicators of treatment response.
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